Hunan Jiudian Pharmaceutical Co Ltd
Hunan Jiudian Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. Its products portfolio includes Pantoprazole Sodium Enteric-coated, Ferrous Succinate, Rosuvastatin Calcium, Ebastine, and Rabeprazole Sodium Enteric-coated Tablets; and Acetylcysteine Granules, Potassium Sodium Hydrogen Citrate Granules, Loxoprofen Sodium Gel Pat… Read more
Market Cap & Net Worth: Hunan Jiudian Pharmaceutical Co Ltd (300705)
Hunan Jiudian Pharmaceutical Co Ltd (SHE:300705) has a market capitalization of $1.00 Billion (CN¥7.35 Billion) as of March 18, 2026. Listed on the SHE stock exchange, this China-based company holds position #10001 globally and #2144 in its home market, demonstrating a -1.41% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Jiudian Pharmaceutical Co Ltd's stock price CN¥14.70 by its total outstanding shares 500212488 (500.21 Million).
Hunan Jiudian Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Hunan Jiudian Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows growth from $433.13 Million to $1.00 Billion (18.03% CAGR).
Hunan Jiudian Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Jiudian Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.42x
Hunan Jiudian Pharmaceutical Co Ltd's market cap is 0.42 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
2.39x
Hunan Jiudian Pharmaceutical Co Ltd's market cap is 2.39 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $433.13 Million | $534.52 Million | $68.57 Million | 0.81x | 6.32x |
| 2018 | $389.56 Million | $801.38 Million | $71.99 Million | 0.49x | 5.41x |
| 2019 | $409.76 Million | $924.06 Million | $55.07 Million | 0.44x | 7.44x |
| 2020 | $896.48 Million | $978.16 Million | $82.26 Million | 0.92x | 10.90x |
| 2021 | $1.18 Billion | $1.63 Billion | $204.25 Million | 0.72x | 5.76x |
| 2022 | $1.16 Billion | $2.33 Billion | $269.70 Million | 0.50x | 4.29x |
| 2023 | $1.60 Billion | $2.69 Billion | $368.26 Million | 0.59x | 4.34x |
| 2024 | $1.22 Billion | $2.93 Billion | $512.38 Million | 0.42x | 2.39x |
Competitor Companies of 300705 by Market Capitalization
Companies near Hunan Jiudian Pharmaceutical Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Hunan Jiudian Pharmaceutical Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Hunan Jiudian Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Hunan Jiudian Pharmaceutical Co Ltd's market cap moved from $433.13 Million to $ 1.00 Billion, with a yearly change of 18.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.00 Billion | -1.87% |
| 2025 | CN¥1.02 Billion | -16.55% |
| 2024 | CN¥1.22 Billion | -23.41% |
| 2023 | CN¥1.60 Billion | +38.04% |
| 2022 | CN¥1.16 Billion | -1.67% |
| 2021 | CN¥1.18 Billion | +31.30% |
| 2020 | CN¥896.48 Million | +118.78% |
| 2019 | CN¥409.76 Million | +5.18% |
| 2018 | CN¥389.56 Million | -10.06% |
| 2017 | CN¥433.13 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hunan Jiudian Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.00 Billion USD |
| MoneyControl | $1.00 Billion USD |
| MarketWatch | $1.00 Billion USD |
| marketcap.company | $1.00 Billion USD |
| Reuters | $1.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.